American Journal of Kidney Diseases
Volume 56, Issue 6 , Pages 1158-1162 , December 2010

Rapidly Progressive Severe Vascular Calcification Sparing the Kidney Allograft Following Warfarin Initiation

  • Marta Hristova, MD, PhD

      Affiliations

    • Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA
    • Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA
    • Corresponding Author InformationAddress correspondence to Marta Hristova, MD, PhD, 185 Pilgrim Rd, Farr8 Renal Unit, Beth Israel Deaconess Medical Center, Boston, MA 02215
    • ,
  • Christine van Beek, MD

      Affiliations

    • Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA
    • ,
  • Leon J. Schurgers, PhD

      Affiliations

    • Cardiovascular Research Institute and VitaK, University of Maastricht, Maastricht, the Netherlands
    • ,
  • Beate Lanske, PhD

      Affiliations

    • Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA
    • ,
  • John Danziger, MD

      Affiliations

    • Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA

Received 19 March 2010 ,Accepted 22 June 2010.

References 

  1. Danziger J. Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol. 2008;3:1504–1510
  2. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol. 1998;18:1400–1407
  3. Coates T, Kirkland GS, Dymock RB, et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis. 1998;32:384–391
  4. Holden RM, Sanfilippo AS, Hopman WM, Zimmerman D, Garland JS, Morton AR. Warfarin and aortic valve calcification in hemodialysis patients. J Nephrol. 2007;20:417–422
  5. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20:2223–2233
  6. Schurgers LJ, Aebert H, Vermeer C, Bultmann B, Janzen J. Oral anticoagulant treatment: friend or foe in cardiovascular disease?. Blood. 2004;104:3231–3232
  7. Koos R, Mahnken AH, Muhlenbruch G, et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol. 2005;96:747–749
  8. Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin-induced skin necrosis. J Am Acad Dermatol. 2009;61:325–332
  9. Murshed M, Schinke T, McKee MD, Karsenty G. Extracellular matrix mineralization is regulated locally; different roles of two Gla-containing proteins. J Cell Biol. 2004;165:625–630
  10. Kobayashi N, Kitazawa R, Maeda S, Schurgers L, Kitazawa S. T-138C polymorphism of matrix Gla protein promoter alters its expression but is not directly associated with atherosclerotic vascular calcification. Kobe J Med Sci. 2004;50:69–81
  11. Herrmann SM, Whatling C, Brand E, et al. Polymorphisms of the human matrix Gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol. 2000;20:2386–2393
  12. Schurgers LJ, Teunissen KJ, Knapen MH, et al. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol. 2005;25:1629–1633

 Originally published online as doi:10.1053/j.ajkd.2010.06.017 on September 3, 2010.

PII: S0272-6386(10)01086-3

doi: 10.1053/j.ajkd.2010.06.017

American Journal of Kidney Diseases
Volume 56, Issue 6 , Pages 1158-1162 , December 2010

Article Tools

* Image Usage & Resolution